SCHEMBL6790627

SCHEMBL6790627

CN(C)c1cc(Nc2ccc(Cl)c(Cl)c2)nc(Nc2ccccc2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.58
NPY5R Q15761 1/20 0.54
SLC2A1 P11166 2/20 0.51
ALDH1A1 P00352 1/20 0.47
POLA1 P09884 1/20 0.45
TGM2 P21980 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPT P10636 3/20 0.43
NFKB1 P19838 1/20 0.43
MAPK1 P28482 1/20 0.43
LMNA P02545 3/20 0.42
KDM4E B2RXH2 2/20 0.42
HTT P42858 2/20 0.42
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
IGF1R P08069 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6784490 0.90 TAAR1 (0.59) TAAR1NPY5RSLC2A1ALDH1A1TGM2
SCHEMBL8084560 0.90 TAAR1 (0.59) TAAR1NPY5RSLC2A1ALDH1A1TGM2
SCHEMBL4415371 0.90 APP (0.50) TAAR1NPY5RSLC2A1POLA1MAPT
SCHEMBL6791894 0.87 TAAR1 (0.73) TAAR1SLC2A1ALDH1A1TGM2MEN1
SCHEMBL6789185 0.82 TAAR1 (0.62) TAAR1SLC2A1ALDH1A1TGM2MEN1
SCHEMBL6789489 0.80 TAAR1 (0.59) TAAR1SLC2A1ALDH1A1TGM2MAPT
SCHEMBL6790294 0.80 TAAR1 (0.59) TAAR1SLC2A1ALDH1A1TGM2MEN1
SCHEMBL10144336 0.79 TAAR1 (0.53) TAAR1SLC2A1ALDH1A1MEN1KMT2A
SCHEMBL3244058 0.79 TAAR1 (0.69) TAAR1SLC2A1ALDH1A1TGM2MEN1
SCHEMBL3247948 0.77 TAAR1 (0.56) TAAR1SLC2A1MAPTNFKB1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2140864-A2 Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods H.Lundbeck A/S (DK) 2010-01-06 EP disclosed
US-20040127502-A1 Use of GAL3 antagonist for treatment of depression SYNAPTIC PHARMACEUTICAL CORPORATION 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127502-A1 Use of GAL3 antagonist for treatment of depression GALR3, GALR2, GALR1 TAAR1 270/4885NPY5R 123/4885SLC2A1 1700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.